Therapeutic decisions in breast cancer (BC) are, among other factors, based on the expression of the predictive markers on the primary tumor (PT): the estrogen-(ER) and progesterone receptor (PR) as well as the epidermal growth factor receptor HER2 [1]. This evidence concerns the gene ERBB2 and breast carcinoma.